7 canonical passages across 5 cases, quoted by 38 opinions in total. These passages cluster together because the same opinions keep quoting them side by side — they state parts of one doctrine. The anchor passage is from Hybritech Incorporated v. Monoclonal Antibodies, Inc..
| # | Case | Flag | Canonical passage | Citers |
|---|---|---|---|---|
| 1 | Hybritech Incorporated v. Monoclonal Antibodies, Inc. Anchor | green | “a patent need not teach, and preferably omits, what is well known in the art.” | 11 |
| 2 | Alza Corp. v. Andrx Pharmaceuticals, LLC | green | “is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations.” | 6 |
| 3 | In Re Jack R. Wands, Vincent R. Zurawski, Jr., and Hubert J.P. Schoemaker | green | “enablement is not precluded by the necessity for some experimentation such as routine screening.” | 5 |
| 4 | Signtech Usa, Ltd. v. Vutek, Inc. | green | “from otherwise infringing the asserted claims,” | 4 |
| 5 | Streck, Inc. v. Research & Diagnostic Systems, Inc. | green | “no 'reasonable apprehension' it will face an infringement suit on any claims other than those that streck asserts it has infringed in this action.” | 4 |
| 6 | Streck, Inc. v. Research & Diagnostic Systems, Inc. | green | “johnson inventions anticipate each claim asserted by streck, including at least claims 28 and 29 of the '500 patent, claims 1, 4, 5, 6, 8-9, 13, 15, and 26-29 of the '668 patent, and claim 13 of the '388 patent.” | 4 |
| 7 | Streck, Inc. v. Research & Diagnostic Systems, Inc. | green | “related to the commercial practicalities of use of true reticulocytes on a large scale and not to the feasibility or viability of true reticulocytes in a control.” | 4 |
A red or yellow flag on a member means the underlying case has negative treatment — for those, check the case page before relying on the passage.